Theranos Whistleblower Tyler Shultz Warns AI Boom Invites Fraud

Theranos peaked at a $10 billion valuation on technology that never worked — and the whistleblower who exposed it says the AI boom is handing the same playbook to a new generation of founders. Tyler Shultz, whose first job out of college was at Theranos, told the San Francisco Standard that the current funding environment is, in his words, "a great opportunity to go deceive people."

His timing is not accidental. Shultz spoke out as "You Can See Everything," a documentary directed by Nathan Fielder and Lance Oppenheim, becomes one of the highest-grossing documentaries of all time. The film captures Elizabeth Holmes' final weeks with her family before she surrendered to serve a federal prison sentence of more than eleven years.

Why is Theranos relevant again?

Shultz, grandson of former U.S. Secretary of State and Treasury Secretary George Shultz — himself a Theranos investor and board member — sees the renewed attention on Holmes as deliberate. He put it bluntly:

"The only reason we're talking about Elizabeth Holmes right now is because she wants us to be talking about Elizabeth Holmes right now."

The documentary's premise invites that reading. It follows a mother of two young children through her last days of freedom, and it pointedly refuses to frame her as either master manipulator or victim. Instead, it highlights what the directors see as her uncanny, almost hypnotic knack for making people pity her — even people who know exactly what she did.

That pity, Shultz suggests, could be worth more to Holmes than hate or mockery ever were.

The takeaway: the film is a media event, but the financial lesson it gestures at is the one Shultz wants investors to remember.

What was the actual damage?

Theranos' blood-testing devices were dangerously inaccurate, yet they made their way into Walgreens stores and delivered faulty results to real patients. The company ran only a fraction of its tests on its own machines and quietly outsourced the rest to third-party equipment while claiming proprietary breakthroughs.

The funding model mattered as much as the technology. Theranos raised much of its money from wealthy individuals — the DeVos and Walton families among them — rather than from venture firms. It refused to share scientific evidence its machines worked, citing trade secrets, which kept many top Silicon Valley VCs away but didn't stop the checks.

Shultz's own experience with the company went beyond faulty lab results. Theranos targeted and harassed him personally when he tried to sound the alarm about his former employer — a chapter the documentary glosses over, along with the patient harm.

In the cultural zeitgeist, Holmes remains more of a joke than a persona non grata. The money she took was real.

What does Shultz want investors to change?

His core prescription is about speed and trust. The casual angel-check era, he argues, should be over:

"I think the days of having a thirty-minute coffee with someone and sending them $100,000 should be over. Elizabeth took that model and scaled it to $100 million."

He frames Theranos itself as an outlier of that same dynamic: "I believe that what [Holmes] did was raise the biggest angel round of funding of all time, but even at the smaller levels, I think investors need to recognize that when they put that type of money in someone's hands, they are giving them tremendous power."

The practical takeaway: capital is leverage, and diligence-free capital is leverage handed to strangers.

Why is AI diligence so hard?

Here is where Shultz's warning turns to the present. Companies that have never turned a profit are raising capital at trillion-dollar valuations, and he thinks the technology itself defeats the standard vetting toolkit.

"A huge danger with AI is that I think it is really hard to do due diligence on it," he said. "It's really hard to tell the difference between what is something truly unique and new versus like, a ChatGPT wrapper… If you want to deceive people, I think this is a great opportunity to go deceive people."

That's the sharpest line in the interview, and it lands on a real asymmetry. A blood test can be validated against known samples. A proprietary AI model, shielded by claims of trade secrets, resists the same scrutiny — the exact defense Theranos used to dodge investor questions a decade ago.

When the fraud was uncovered, it read as a wake-up call on due diligence. Shultz worries investors are sleeping through the alarm a second time.

Is Holmes planning a comeback?

The documentary supplies the uncomfortable coda. In the film, Holmes and her partner, hotel heir Billy Evans, work on Haemanthus, a diagnostics company they reportedly call "Theranos 2.0." It has raised about $20 million in funding.

Shultz has watched that development with visible unease:

"I have this feeling of unease about what might come next. She's certainly preparing and beginning her second act, and I don't know exactly where it's going to go."

For investors writing checks in the AI era, his message reduces to one sentence: if you can't tell a breakthrough from a wrapper, you're not doing diligence — you're doing the coffee meeting.